Standard arm (Arm A): Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)

Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease.

Experimental arm (Arm B):

• 0.4 to 1 ml of NAC 10% through intratympanic injection (ITI) from 40 to 60 minutes maximum prior to each Cisplatin cycle.
• Cisplatin from 70 to 100 mg/m2 intravenous (IV) once for 3 to 7 cycles +/- Radiotherapy (depending on the type and the severity of the neoplastic disease)

Dosis and number of Cisplatin cycles are determined by the oncologist depending on type and severity of neoplastic disease.

Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears

the apparition of ototoxicity as defined by the International Common Terminology Criteria for Adverse Events (CTCAE), version 5:

• A Threshold shift of 15 - 25 decibel (dB) averaged at 2 contiguous test frequencies in at least one ear
• and/or the apparition of a tinnitus (not previously present).

the apparition of ototoxicity as defined by the International Common Terminology Criteria for Adverse Events (CTCAE), version 5:

• A Threshold shift of 15 - 25 dB averaged at 2 contiguous test frequencies in at least one ear
• and/or the apparition of a tinnitus (not previously present).